{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:07:04Z","timestamp":1791655624626,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40262-026-01628-2","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:28:38Z","timestamp":1773062918000},"page":"681-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods"],"prefix":"10.1007","volume":"65","author":[{"given":"F\u00e9licien","family":"Le Louedec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Vachoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malika","family":"Yakoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Thuillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"White-Koning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Puisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7740-9096","authenticated-orcid":false,"given":"\u00c9tienne","family":"Chatelut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/bcp.14185","volume":"86","author":"K Westerdijk","year":"2020","unstructured":"Westerdijk K, Desar IME, Steeghs N, van der Graaf WTA, van Erp NP. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86:258\u201373. https:\/\/doi.org\/10.1111\/bcp.14185.","journal-title":"Br J Clin Pharmacol"},{"key":"1628_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000699","volume":"42","author":"E Cardoso","year":"2020","unstructured":"Cardoso E, Guidi M, Blanchet B, Schneider MP, Decosterd LA, Buclin T, et al. Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: a critical review. Ther Drug Monit. 2020;42:33. https:\/\/doi.org\/10.1097\/FTD.0000000000000699.","journal-title":"Ther Drug Monit"},{"key":"1628_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318292b931","volume":"35","author":"DH Josephs","year":"2013","unstructured":"Josephs DH, Fisher DS, Spicer J, Flanagan RJ. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit. 2013;35:562. https:\/\/doi.org\/10.1097\/FTD.0b013e318292b931.","journal-title":"Ther Drug Monit"},{"key":"1628_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","volume":"77","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77:441\u201364. https:\/\/doi.org\/10.1007\/s00228-020-03014-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"1628_CR5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s40262-016-0503-3","volume":"56","author":"RWF van Leeuwen","year":"2017","unstructured":"van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, et al. Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options. Clin Pharmacokinet. 2017;56:683\u20138. https:\/\/doi.org\/10.1007\/s40262-016-0503-3.","journal-title":"Clin Pharmacokinet"},{"key":"1628_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40262-022-01200-8","volume":"62","author":"F Le Louedec","year":"2023","unstructured":"Le Louedec F, Puisset F, Chatelut E, Tod M. Considering the oral bioavailability of protein kinase inhibitors: essential in assessing the extent of drug-drug interaction and improving clinical practice. Clin Pharmacokinet. 2023;62:55\u201366. https:\/\/doi.org\/10.1007\/s40262-022-01200-8.","journal-title":"Clin Pharmacokinet"},{"key":"1628_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010313","volume":"15","author":"F Puisset","year":"2023","unstructured":"Puisset F, Mseddi M, Mourey L, Pouessel D, Blanchet B, Chatelut E, et al. Therapeutic drug monitoring of tyrosine kinase inhibitors in the treatment of advanced renal cancer. Cancers (Basel). 2023;15:313. https:\/\/doi.org\/10.3390\/cancers15010313.","journal-title":"Cancers (Basel)"},{"key":"1628_CR8","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrd2380","volume":"6","author":"S Faivre","year":"2007","unstructured":"Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6:734\u201345. https:\/\/doi.org\/10.1038\/nrd2380.","journal-title":"Nat Rev Drug Discov"},{"key":"1628_CR9","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1909\u201316. https:\/\/doi.org\/10.1038\/bjc.2014.503.","journal-title":"Br J Cancer"},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/FTD.0000000000000141","volume":"37","author":"D de Wit","year":"2015","unstructured":"de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit. 2015;37:331\u20138. https:\/\/doi.org\/10.1097\/FTD.0000000000000141.","journal-title":"Ther Drug Monit"},{"key":"1628_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421","volume":"215","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215:115421. https:\/\/doi.org\/10.1016\/j.addr.2024.115421.","journal-title":"Adv Drug Deliv Rev"},{"key":"1628_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.annonc.2022.06.010","volume":"33","author":"SL Groenland","year":"2022","unstructured":"Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann Oncol. 2022;33:1071\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2022.06.010.","journal-title":"Ann Oncol"},{"key":"1628_CR13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/FTD.0000000000000767","volume":"42","author":"JM Janssen","year":"2020","unstructured":"Janssen JM, Dorlo TPC, Beijnen JH, Huitema ADR. Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs. Ther Drug Monit. 2020;42:532\u20139. https:\/\/doi.org\/10.1097\/FTD.0000000000000767.","journal-title":"Ther Drug Monit"},{"key":"1628_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00177","volume":"11","author":"T Buclin","year":"2020","unstructured":"Buclin T, Thoma Y, Widmer N, Andr\u00e9 P, Guidi M, Csajka C, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with Imatinib. Front Pharmacol. 2020;11:177. https:\/\/doi.org\/10.3389\/fphar.2020.00177.","journal-title":"Front Pharmacol"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","volume":"7","author":"RJ Keizer","year":"2018","unstructured":"Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-informed precision dosing at the bedside: scientific challenges and opportunities. CPT Pharmacomet Syst Pharmacol. 2018;7:785\u20137. https:\/\/doi.org\/10.1002\/psp4.12353.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1628_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cpt.2049","volume":"109","author":"F Kluwe","year":"2021","unstructured":"Kluwe F, Michelet R, Mueller-Schoell A, Maier C, Klopp-Schulze L, van Dyk M, et al. Perspectives on model-informed precision dosing in the digital health era: challenges, opportunities, and recommendations. Clin Pharmacol Ther. 2021;109:29\u201336. https:\/\/doi.org\/10.1002\/cpt.2049.","journal-title":"Clin Pharmacol Ther"},{"key":"1628_CR17","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","volume":"109","author":"SG Wicha","year":"2021","unstructured":"Wicha SG, M\u00e4rtson A-G, Nielsen EI, Koch BCP, Friberg LE, Alffenaar J-W, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109:928\u201341. https:\/\/doi.org\/10.1002\/cpt.2202.","journal-title":"Clin Pharmacol Ther"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cpt.2065","volume":"109","author":"DW Uster","year":"2021","unstructured":"Uster DW, Stocker SL, Carland JE, Brett J, Marriott DJE, Day RO, et al. A model averaging\/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study. Clin Pharmacol Ther. 2021;109:175\u201383. https:\/\/doi.org\/10.1002\/cpt.2065.","journal-title":"Clin Pharmacol Ther"},{"key":"1628_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/psp4.12813","volume":"11","author":"W Kantasiripitak","year":"2022","unstructured":"Kantasiripitak W, Outtier A, Wicha SG, Kensert A, Wang Z, Sabino J, et al. Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT Pharmacomet Syst Pharmacol. 2022;11:1045\u201359. https:\/\/doi.org\/10.1002\/psp4.12813.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1628_CR20","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/psp4.12684","volume":"10","author":"JH Hughes","year":"2021","unstructured":"Hughes JH, Keizer RJ. A hybrid machine learning\/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacomet Syst Pharmacol. 2021;10:1150\u201360. https:\/\/doi.org\/10.1002\/psp4.12684.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1628_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106416","volume":"186","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wang C, Chen Y, Wang X, Jiao Z, Wang Z. External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients. Eur J Pharm Sci. 2023;186:106416. https:\/\/doi.org\/10.1016\/j.ejps.2023.106416.","journal-title":"Eur J Pharm Sci"},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"1286.e1","DOI":"10.1016\/j.cmi.2019.02.029","volume":"25","author":"A Broeker","year":"2019","unstructured":"Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, et al. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clin Microbiol Infect. 2019;25:1286.e1-1286.e7. https:\/\/doi.org\/10.1016\/j.cmi.2019.02.029.","journal-title":"Clin Microbiol Infect"},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1111\/bcp.14360","volume":"86","author":"R Ter Heine","year":"2020","unstructured":"Ter Heine R, Keizer RJ, van Steeg K, Smolders EJ, van Luin M, Derijks HJ, et al. Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. Br J Clin Pharmacol. 2020;86:2497\u2013506. https:\/\/doi.org\/10.1111\/bcp.14360.","journal-title":"Br J Clin Pharmacol"},{"key":"1628_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/11596990-000000000-00000","volume":"51","author":"V Gotta","year":"2012","unstructured":"Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, et al. Therapeutic drug monitoring of imatinib. Clin Pharmacokinet. 2012;51:187\u2013201. https:\/\/doi.org\/10.2165\/11596990-000000000-00000.","journal-title":"Clin Pharmacokinet"},{"key":"1628_CR25","unstructured":"European Medecines Agency. Sutent: EPAR\u2014product information. Annex I\u2014summary of product characteristics. Amsterdam: EMA; 2009 [cited 2019 Jul 23]. https:\/\/www.ema.europa.eu\/documents\/product-information\/sutent-epar-product-information_en.pdf. Accessed 23 Jul 2019."},{"key":"1628_CR26","unstructured":"European Medecines Agency. Votrient\u202f: EPAR\u2014product Information. Annex I\u2014summary of product characteristics. Amsterdam: EMA; 2010 [cited 2019 Jul 23]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/votrient-epar-product-information_en.pdf. Accessed 23 Jul 2019."},{"key":"1628_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jpba.2018.03.013","volume":"154","author":"M-N Paludetto","year":"2018","unstructured":"Paludetto M-N, Puisset F, Le Louedec F, Allal B, Lafont T, Chatelut E, et al. Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS\/MS. J Pharm Biomed Anal. 2018;154:373\u201383. https:\/\/doi.org\/10.1016\/j.jpba.2018.03.013.","journal-title":"J Pharm Biomed Anal"},{"key":"1628_CR28","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","volume":"15","author":"BE Houk","year":"2009","unstructured":"Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15:2497\u2013506. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1893.","journal-title":"Clin Cancer Res"},{"key":"1628_CR29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40262-016-0404-5","volume":"55","author":"R Khosravan","year":"2016","unstructured":"Khosravan R, Motzer RJ, Fumagalli E, Rini BI. Population pharmacokinetic\/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor. Clin Pharmacokinet. 2016;55:1251\u201369. https:\/\/doi.org\/10.1007\/s40262-016-0404-5.","journal-title":"Clin Pharmacokinet"},{"key":"1628_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/bcp.12550","volume":"79","author":"H Yu","year":"2015","unstructured":"Yu H, Steeghs N, Kloth JSL, de Wit D, van Hasselt JGC, van Erp NP, et al. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol. 2015;79:809\u201319. https:\/\/doi.org\/10.1111\/bcp.12550.","journal-title":"Br J Clin Pharmacol"},{"key":"1628_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/psp4.12210","volume":"6","author":"MH Diekstra","year":"2017","unstructured":"Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, S\u00f6rgel F, et al. Population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib-treated cancer. CPT Pharmacomet Syst Pharmacol. 2017;6:604\u201313. https:\/\/doi.org\/10.1002\/psp4.12210.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1628_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/clpt.2010.20","volume":"87","author":"A Lindauer","year":"2010","unstructured":"Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, et al. Pharmacokinetic\/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther. 2010;87:601\u20138. https:\/\/doi.org\/10.1038\/clpt.2010.20.","journal-title":"Clin Pharmacol Ther"},{"key":"1628_CR33","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00280-014-2455-3","volume":"73","author":"D-C Imbs","year":"2014","unstructured":"Imbs D-C, N\u00e9grier S, Cassier P, Hollebecque A, Varga A, Blanc E, et al. Pharmacokinetics of pazopanib administered in combination with bevacizumab. Cancer Chemother Pharmacol. 2014;73:1189\u201396. https:\/\/doi.org\/10.1007\/s00280-014-2455-3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1628_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00280-015-2953-y","volume":"77","author":"D-C Imbs","year":"2016","unstructured":"Imbs D-C, Di\u00e9ras V, Bachelot T, Campone M, Isambert N, Joly F, et al. Pharmacokinetic interaction between pazopanib and cisplatin regimen. Cancer Chemother Pharmacol. 2016;77:385\u201392. https:\/\/doi.org\/10.1007\/s00280-015-2953-y.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1628_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/ph14090927","volume":"14","author":"AC Ozbey","year":"2021","unstructured":"Ozbey AC, Combarel D, Poinsignon V, Lovera C, Saada E, Mir O, et al. Population pharmacokinetic analysis of pazopanib in patients and determination of target AUC. Pharmaceuticals (Basel). 2021;14:927. https:\/\/doi.org\/10.3390\/ph14090927.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1628_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40262-016-0443-y","volume":"56","author":"H Yu","year":"2016","unstructured":"Yu H, van Erp N, Bins S, Mathijssen RHJ, Schellens JHM, Beijnen JH, et al. Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. Clin Pharmacokinet. 2016;56:293\u2013303. https:\/\/doi.org\/10.1007\/s40262-016-0443-y.","journal-title":"Clin Pharmacokinet"},{"key":"1628_CR37","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jgo.2021.02.006","volume":"12","author":"L Mourey","year":"2021","unstructured":"Mourey L, Le Louedec F, Ravaud A, Paludetto M-N, Digue L, Gomez-Roca CA, et al. VOTRAGE study: phase I dose-escalation study of pazopanib in unfit older patients. J Geriatr Oncol. 2021;12:759\u201364. https:\/\/doi.org\/10.1016\/j.jgo.2021.02.006.","journal-title":"J Geriatr Oncol"},{"key":"1628_CR38","unstructured":"Baneyx G, Combes FP, Huang P-H, Elmeliegy M. Population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma. PAGE meeting; 2017 [cited 2019 Jul 26]. https:\/\/www.page-meeting.org\/pdf_assets\/6943-PZP034popPK_PAGE2017v4.pdf. Accessed 26 Jul 2019."},{"key":"1628_CR39","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/BF01113502","volume":"21","author":"MO Karlsson","year":"1993","unstructured":"Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 1993;21:735\u201350.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1628_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10928-015-9459-4","volume":"43","author":"M Lavielle","year":"2016","unstructured":"Lavielle M, Aarons L. What do we mean by identifiability in mixed effects models? J Pharmacokinet Pharmacodyn. 2016;43:111\u201322. https:\/\/doi.org\/10.1007\/s10928-015-9459-4.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1628_CR41","doi-asserted-by":"publisher","DOI":"10.4196\/kjpp.2012.16.2.97","volume":"16","author":"D Kang","year":"2012","unstructured":"Kang D, Bae K-S, Houk BE, Savic RM, Karlsson MO. Standard error of empirical Bayes estimate in NONMEM\u00ae VI. Korean J Physiol Pharmacol. 2012;16:97. https:\/\/doi.org\/10.4196\/kjpp.2012.16.2.97.","journal-title":"Korean J Physiol Pharmacol"},{"key":"1628_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40262-021-01105-y","volume":"61","author":"S Baklouti","year":"2022","unstructured":"Baklouti S, Gandia P, Concordet D. \u201cDe-shrinking\u201d EBEs: the solution for Bayesian therapeutic drug monitoring. Clin Pharmacokinet. 2022;61:749\u201357. https:\/\/doi.org\/10.1007\/s40262-021-01105-y.","journal-title":"Clin Pharmacokinet"},{"key":"1628_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/psp4.12467","volume":"8","author":"A Elmokadem","year":"2019","unstructured":"Elmokadem A, Riggs MM, Baron KT. Quantitative systems pharmacology and physiologically-based pharmacokinetic modeling with mrgsolve: a hands-on tutorial. CPT Pharmacomet Syst Pharmacol. 2019;8:883\u201393. https:\/\/doi.org\/10.1002\/psp4.12467.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1628_CR44","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/psp4.12689","volume":"10","author":"F Le Louedec","year":"2021","unstructured":"Le Louedec F, Puisset F, Thomas F, Chatelut \u00c9, White-Koning M. Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr. CPT Pharmacomet Syst Pharmacol. 2021;10:1208\u201320. https:\/\/doi.org\/10.1002\/psp4.12689.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1628_CR45","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W, McGowan LD, Fran\u00e7ois R, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4:1686. https:\/\/doi.org\/10.21105\/joss.01686.","journal-title":"J Open Source Softw"},{"key":"1628_CR46","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s11095-023-03507-y","volume":"40","author":"A Destere","year":"2023","unstructured":"Destere A, Marquet P, Labriffe M, Drici M-D, Woillard J-B. A hybrid algorithm combining population pharmacokinetic and machine learning for isavuconazole exposure prediction. Pharm Res. 2023;40:951\u20139. https:\/\/doi.org\/10.1007\/s11095-023-03507-y.","journal-title":"Pharm Res"},{"key":"1628_CR47","unstructured":"Wicha SG, Henning S. Handling inter-occasion variability in model implementation for Bayesian forecasting: A comparison of methods and metrics. PAGE 27. Montreux, Switzerland; 2018. www.page-meeting.org\/?abstract=8580."},{"key":"1628_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02908-7","volume":"37","author":"T Guo","year":"2020","unstructured":"Guo T, van Hest RM, Zwep LB, Roggeveen LF, Fleuren LM, Bosman RJ, et al. Optimizing predictive performance of Bayesian forecasting for vancomycin concentration in intensive care patients. Pharm Res. 2020;37:171. https:\/\/doi.org\/10.1007\/s11095-020-02908-7.","journal-title":"Pharm Res"},{"key":"1628_CR49","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/psp4.12286","volume":"7","author":"A K\u00fcmmel","year":"2018","unstructured":"K\u00fcmmel A, Bonate PL, Dingemanse J, Krause A. Confidence and prediction intervals for pharmacometric models. CPT Pharmacomet Syst Pharmacol. 2018;7:360\u201373. https:\/\/doi.org\/10.1002\/psp4.12286.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1628_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020442","volume":"14","author":"C Leven","year":"2022","unstructured":"Leven C, Coste A, Man\u00e9 C. Free and open-source posologyr software for Bayesian dose individualization: an extensive validation on simulated data. Pharmaceutics. 2022;14:442. https:\/\/doi.org\/10.3390\/pharmaceutics14020442.","journal-title":"Pharmaceutics"},{"key":"1628_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020127","volume":"15","author":"S Lee","year":"2022","unstructured":"Lee S, Song M, Lim W, Song E, Han J, Kim B-H. Development and validation of open-source R package HMCtdm for therapeutic drug monitoring. Pharmaceuticals (Basel). 2022;15:127. https:\/\/doi.org\/10.3390\/ph15020127.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1628_CR52","unstructured":"Tong DM, Hughes JH, Keizer RJ. Comparing full Bayesian estimation to maximum a posteriori (MAP) Bayesian estimation in three routine clinical care scenarios. PAGE 30. Ljubljana, Slovenia; 2022. www.page-meeting.org\/default.asp?abstract=10233."},{"key":"1628_CR53","unstructured":"Chang W, Cheng J, Allaire JJ, Sievert C, Schloerke B, Xie Y, et al. shiny: web application framework for R. Posit Software, PBC; 2024. https:\/\/shiny.posit.co\/."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01628-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01628-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01628-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:50:36Z","timestamp":1779119436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01628-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01628-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data and material are available upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of \u201cSUD-OUEST ET OUTRE MER III\u201d on August 26, 2015.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Conceptualization: F\u00e9licien Le Louedec; Methodology: F\u00e9licien Le Louedec; Patient recruitment: Loic Mourey, Diego Tosi, Gwenaelle Gravis-Mescam, Guilhem Roubaud, Fr\u00e9d\u00e9ric Thuillier, Helen Boyle; Data acquisition: Maud Maillard, Christelle Vachoux, Malika Yakoubi; Formal analysis: F\u00e9licien Le Louedec, Laura Morvan; Writing\u2014original draft preparation: F\u00e9licien Le Louedec; Writing\u2014review and editing: Fabienne Thomas, M\u00e9lanie White-Koning, Florent Puisset, \u00c9tienne Chatelut; Supervision: \u00c9tienne Chatelut.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}